Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with ...

Novo Nordisk’s sharp decline may have opened the door for a massive rebound here’s why investors are watching its ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United ...

Hims & Hers said that the discussions with Novo Nordisk (DK:NOVO.B) are ongoing, that "no definitive agreement" has been reached, and that the two companies may not reach one. Nonetheless, Hims & Hers ...

Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Pfizer today announced that it has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk in the US District Court for the District of Delaware.

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...

Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, Palantir (NASDAQ:PLTR), Robinhood, Super Micro Computer, Qualcomm, ARM ...

Scottish patients placed at the heart of a multi-million pound study of weight-loss medicines. Scottish patients placed at the heart of a ...